Potential clinical application of interleukin-27 as an antitumor agent

Cancer Science

Volumn 106, Issue 9, 2015, Pages 1103-1110

  Yoshimoto, Takayuki ^a   Chiba, Yukino ^a   Furusawa, Jun Ichi ^a   Xu, Mingli ^a   Tsunoda, Ren ^a   Higuchi, Kaname ^a   Mizoguchi, Izuru ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antitumor effects; IL 10; IL 27; Protumor effects; Treg

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; MUCIN 3; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P28; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; DRUG POTENCY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-27; NEOPLASMS;

EID: 84942193300     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12731     Document Type: Review

References (67)

1. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
2. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
3. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
4. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-42.
5. Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol 2004; 173: 715-20.
6. Mizoguchi I, Higuchi K, Mitobe K, Tsunoda R, Mizuguchi J, Yoshimoto T. Interleukin-27: Regulation of immune responses and disease development by a pleiotropic cytokine with pro- and anti-inflammatory properties. In: Yoshimoto T, Yoshimoto T, eds. Cytokine Frontiers: Regulation of Immune Responses in Health and Disease. Tokyo: Springer, 2013; 353-75.
7. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol 2015; 33: 417-43.
8. Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. J Immunol 2005; 175: 1686-93.
9. Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naive CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol 2011; 41: 47-59.
10. Awasthi A, Carrier Y, Peron JP et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007; 8: 1380-9.
11. Fitzgerald DC, Zhang GX, El-Behi M et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007; 8: 1372-9.
12. Stumhofer JS, Silver JS, Laurence A et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007; 8: 1363-71.
13. Neufert C, Becker C, Wirtz S et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 2007; 37: 1809-16.
14. Huber M, Steinwald V, Guralnik A et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 2008; 20: 223-34.
15. Wojno ED, Hosken N, Stumhofer JS et al. A role for IL-27 in limiting T regulatory cell populations. J Immunol 2011; 187: 266-73.
16. Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med 2011; 208: 115-23.
17. Hall AO, Beiting DP, Tato C et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 2012; 37: 511-23.
18. Karakhanova S, Bedke T, Enk AH, Mahnke K. IL-27 renders DC immunosuppressive by induction of B7-H1. J Leukoc Biol 2011; 89: 837-45.
19. Matta BM, Raimondi G, Rosborough BR, Sumpter TL, Thomson AW. IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J Immunol 2012; 188: 5227-37.
20. Hirahara K, Ghoreschi K, Yang XP et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012; 36: 1017-30.
21. Hisada M, Kamiya S, Fujita K et al. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64: 1152-6.
22. Oniki S, Nagai H, Horikawa T et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006; 66: 6395-404.
23. Salcedo R, Stauffer JK, Lincoln E et al. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004; 173: 7170-82.
24. Chiyo M, Shimozato O, Yu L et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005; 115: 437-42.
25. Hu P, Hu HD, Chen M et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol 2009; 46: 1654-62.
26. Salcedo R, Hixon JA, Stauffer JK et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009; 182: 4328-38.
27. Zhu S, Lee DA, Li S. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 2010; 184: 2348-54.
28. Zolochevska O, Xia X, Williams BJ, Ramsay A, Li S, Figueiredo ML. Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum Gene Ther 2011; 22: 1537-50.
29. Liu Z, Liu JQ, Talebian F, Wu LC, Li S, Bai XF. IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells. Eur J Immunol 2013; 43: 468-79.
30. Zhang J, Tian H, Li C et al. Antitumor effects obtained by autologous Lewis lung cancer cell vaccine engineered to secrete mouse interleukin 27 by means of cationic liposome. Mol Immunol 2013; 55: 264-74.
31. Liu L, Wang S, Shan B et al. IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J Immunol 2008; 68: 22-9.
32. Airoldi I, Tupone MG, Esposito S et al. Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer. Oncotarget 2015; 6: 3694-708.
33. Matsui M, Kishida T, Nakano H et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res 2009; 69: 2523-30.
34. Shimizu M, Shimamura M, Owaki T et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176: 7317-24.
35. Cocco C, Giuliani N, Di Carlo E et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010; 16: 4188-97.
36. Canale S, Cocco C, Frasson C et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 2011; 25: 1815-24.
37. Cocco C, Di Carlo E, Zupo S et al. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia 2012; 26: 1365-74.
38. Zorzoli A, Di Carlo E, Cocco C et al. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res 2012; 18: 1630-40.
39. Kachroo P, Lee MH, Zhang L et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res 2013; 32: 97.
40. Di Carlo E, Sorrentino C, Zorzoli A et al. The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget 2014; 5: 10332-41.
41. Yoshimoto T, Morishima N, Mizoguchi I et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008; 180: 6527-35.
42. Liu L, Meng J, Zhang C et al. Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells. Oncol Rep 2012; 27: 1497-503.
43. Chiba Y, Mizoguchi I, Mitobe K et al. IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS ONE 2013; 8: e76159.
44. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009; 183: 6217-26.
45. Liu LH, Shan BE, Shao LL, Wang SJ. Inhibitory effect of IL-27 gene on tumor formation activity of Eca109 cells in nude mice and its mechanisms. Ai Zheng 2008; 27: 12-7.
46. Shinozaki Y, Wang S, Miyazaki Y et al. Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int J Cancer 2009; 124: 1372-8.
47. Natividad KD, Junankar SR, Mohd Redzwan N et al. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS ONE 2013; 8: e57469.
48. Zhu C, Sakuishi K, Xiao S et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun 2015; 6: 6072.
49. Sauer KA, Maxeiner JH, Karwot R et al. Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. J Immunol 2008; 181: 6148-57.
50. Nishino R, Takano A, Oshita H et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 6272-86.
51. Gonin J, Larousserie F, Bastard C et al. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS ONE 2011; 6: e24617.
52. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-9.
53. Wei J, Xia S, Sun H et al. Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells. J Immunol 2013; 191: 500-8.
54. Xia S, Wei J, Wang J et al. A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells. J Leukoc Biol 2014; 95: 733-42.
55. Mumm JB, Emmerich J, Zhang X et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 2011; 20: 781-96.
56. Tanikawa T, Wilke CM, Kryczek I et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012; 72: 420-9.
57. Groux H, Cottrez F, Rouleau M et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999; 162: 1723-9.
58. Trautmann L, Janbazian L, Chomont N et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-202.
59. Jones RB, Ndhlovu LC, Barbour JD et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205: 2763-79.
60. Jin HT, Anderson AC, Tan WG et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010; 107: 14733-8.
61. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011; 350: 17-37.
62. Gonin J, Carlotti A, Dietrich C et al. Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]. PLoS ONE 2013; 8: e75694.
63. Sekar D, Hahn C, Brune B, Roberts E, Weigert A. Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur J Immunol 2012; 42: 1585-98.
64. Reuther GW. JAK2 activation in myeloproliferative neoplasms: a potential role for heterodimeric receptors. Cell Cycle 2008; 7: 714-9.
65. Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci USA 2007; 104: 18502-7.
66. Pradhan A, Lambert QT, Griner LN, Reuther GW. Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J Biol Chem 2010; 285: 16651-63.
67. Seita J, Asakawa M, Ooehara J et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008; 111: 1903-12.